Solid Biosciences Inc.

NasdaqGS SLDB

Solid Biosciences Inc. Current Liabilities for the quarter ending September 30, 2024

Solid Biosciences Inc. Current Liabilities is NA for the quarter ending September 30, 2024. Current liabilities are obligations that are expected to be settled within one year, including accounts payable, short-term debt, and other current liabilities.

Solid Biosciences Inc. Current Liabilities for the quarter ending September 30, 2023 was USD 15.82 M, a -6.55% change year over year.
Solid Biosciences Inc. Current Liabilities for the quarter ending September 30, 2022 was USD 16.93 M, a -24.92% change year over year.
Solid Biosciences Inc. Current Liabilities for the quarter ending September 30, 2021 was USD 22.54 M.

Key data

Date	Current Liabilities	Total Non-Current Liabilities	Shareholders' Equity	Long-Term Debt

NasdaqGS: SLDB

Solid Biosciences Inc.

CEO	Mr. Alexander G. Cumbo
IPO Date	Jan. 26, 2018
Location	United States
Headquarters	141 Portland Street
Employees	88
Sector	Healthcare
Industries Biotechnology

Description

Solid Biosciences Inc. engages in developing therapies for duchenne muscular dystrophy in the United States. The company's lead product candidate is SGT-001, a gene transfer candidate, which is in a Phase I/II clinical trial to drive functional dystrophin protein expression in patients' muscles; and SGT-003, a ext-generation gene transfer candidate for the treatment of duchenne muscular dystrophy. It also engages in developing of platform technologies, including dual gene expression, a technology for packaging multiple transgenes into one vector, as well as novel capsids. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize new gene therapies for Duchenne Muscular Dystrophy. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.

Key trends

Past 5 years